期刊文献+
共找到8篇文章
< 1 >
每页显示 20 50 100
50例乙型病毒肝炎患者临床应用恩替卡韦进行治疗的有效性评价
1
作者 黄艳秋 《中国继续医学教育》 2016年第21期125-127,共3页
目的研究50例乙型病毒肝炎(乙肝)患者临床应用恩替卡韦进行治疗的有效性。方法选取我院50例乙肝患者,随机分为观察组和对照组,每组各25例患者,观察组采用恩替韦卡进行治疗,对照组采用拉米夫定治疗,对比两组治疗前后肝功能指标、超声影... 目的研究50例乙型病毒肝炎(乙肝)患者临床应用恩替卡韦进行治疗的有效性。方法选取我院50例乙肝患者,随机分为观察组和对照组,每组各25例患者,观察组采用恩替韦卡进行治疗,对照组采用拉米夫定治疗,对比两组治疗前后肝功能指标、超声影像学指标等的变化以及治疗后HBV-DNA滴度与转阴率及不良反应。结果观察组与对照组肝功能指标(ALT、ALB及TBil)对比,差异均具有统计学意义(P<0.05,P<0.01)。结论恩替卡韦对乙肝患者具有显著的疗效,安全性更高。 展开更多
关键词 乙肝 恩替韦卡 拉米夫定
下载PDF
恩替卡韦联合天晴甘美治疗乙肝病毒再激活临床疗效观察 被引量:4
2
作者 于桂芹 《青岛医药卫生》 2014年第5期354-355,共2页
目的探讨恩替卡韦和天晴甘美联合对乙型肝炎病毒再激活的治疗效果。方法将乙肝病毒再激活患者84例随机平均分为3组,每组28例。A、B组为对照组,A组:用浓度为150mg/d的天晴甘美静脉注射,当丙氨酸氨基转氨酶达到正常标准后再每日3次服用天... 目的探讨恩替卡韦和天晴甘美联合对乙型肝炎病毒再激活的治疗效果。方法将乙肝病毒再激活患者84例随机平均分为3组,每组28例。A、B组为对照组,A组:用浓度为150mg/d的天晴甘美静脉注射,当丙氨酸氨基转氨酶达到正常标准后再每日3次服用天晴甘美胶囊。B组:口服恩替卡韦,1mg/d。C组:恩替卡韦和天晴甘美联合,用法和剂量与A、B组相同。在接受以上治疗的同时,3组都给予维生素B、C进行辅助治疗。结果经过治疗后,C组的ALT下降幅度比A、B组的明显,总有效率C组也都优于A、B组,结果具有统计学意义(P<0.05)。结论恩替韦卡和天晴甘美联合治疗乙肝病毒再激活有比较显著的疗效,不仅能保肝护肝、还能抗病毒和降酶,值得推广。 展开更多
关键词 乙肝病毒 天晴甘美 恩替韦卡 疗效
下载PDF
恩替卡韦治疗慢性重症乙型肝炎的临床价值分析 被引量:2
3
作者 黄肇权 《北方药学》 2019年第11期31-32,共2页
目的:探讨慢性重症乙型肝炎经恩替卡韦治疗的临床疗效。方法:取我院收治的62例慢性重症乙型肝炎患者作为研究对象,以随机数表法分为对比组与研究组。对比组应用阿德福韦酯治疗,行恩替卡韦治疗研究组。观察两组治疗效果、肝功能。结果:... 目的:探讨慢性重症乙型肝炎经恩替卡韦治疗的临床疗效。方法:取我院收治的62例慢性重症乙型肝炎患者作为研究对象,以随机数表法分为对比组与研究组。对比组应用阿德福韦酯治疗,行恩替卡韦治疗研究组。观察两组治疗效果、肝功能。结果:对比组的治疗有效率为80.65%,明显低于研究组的96.77%;研究组肝功能各指标均低于对比组,差异大(P<0.05)。结论:应用恩替卡韦治疗慢性重症乙型肝炎,效果显著,能对HBV复制予以抑制,有助于肝功能的改善。 展开更多
关键词 慢性重症乙型肝炎 恩替韦卡 治疗效果
下载PDF
恩替卡韦联合护肝降酶药物治疗乙型病毒性肝炎肝硬化患者的疗效 被引量:1
4
作者 汪志文 《医疗装备》 2019年第18期139-140,共2页
目的探讨恩替卡韦联合护肝降酶药物治疗乙型病毒性肝炎肝硬化患者的疗效。方法选取2017年1月至2018年9月万年县人民医院收治的慢性乙型肝炎肝硬化患者86例,随机分为试验组和对照组,各43例。对照组采用益肝灵药物治疗,试验组在对照组基... 目的探讨恩替卡韦联合护肝降酶药物治疗乙型病毒性肝炎肝硬化患者的疗效。方法选取2017年1月至2018年9月万年县人民医院收治的慢性乙型肝炎肝硬化患者86例,随机分为试验组和对照组,各43例。对照组采用益肝灵药物治疗,试验组在对照组基础上加用恩替卡韦药物治疗。比较两组的疗效。结果试验组谷丙转氨酶、谷草转氨酶及总胆红素水平下降程度均高于对照组,差异均有统计学意义(P<0.05)。试验组透明质酸、层黏蛋白、Ⅲ型前胶原肽及Ⅳ型胶原指标均显著低于对照组,差异均有统计学意义(P<0.05)。结论恩替韦卡联合护肝降酶药治疗慢性乙型病毒型肝炎肝硬化患者的疗效显著。 展开更多
关键词 肝硬化 恩替韦卡 护肝降酶药
下载PDF
恩替卡韦抗病毒治疗对失代偿期乙肝肝硬化的干预分析
5
作者 王晓宏 《中文科技期刊数据库(全文版)医药卫生》 2022年第3期115-118,共4页
分析恩替卡韦治疗乙肝肝硬化失代偿期疾病的效果效果。方法:选取我院二〇二〇年二月六日至二〇二二年二月六日期间,研究分组:RES组/REF组;纳入对象:失代偿期乙肝肝硬化患者(36例),分组:RES组(恩替卡韦)/REF组(阿德福韦酯),18例/组。比... 分析恩替卡韦治疗乙肝肝硬化失代偿期疾病的效果效果。方法:选取我院二〇二〇年二月六日至二〇二二年二月六日期间,研究分组:RES组/REF组;纳入对象:失代偿期乙肝肝硬化患者(36例),分组:RES组(恩替卡韦)/REF组(阿德福韦酯),18例/组。比较治疗后两组患者肝功能指标、不良反应发生率、HBV-DNA转阴率。结果:肝功能指标,治疗前两组数据差异较小,无统计学以(P>0.05),治疗后RES组总胆红素(TBLL)、丙氨酸转氨酶(ALT)、白蛋白(ALB)指标分别为(15.62±10.67)mmol/L、(37.19±16.14)U/L、(39.73±3.36)g/L,同指标REF组分别为(23.39±10.26)mmol/L、(53.20±18.65)U/L、(32.52±4.57)g/L,RES组TBLL、ALT指标低于REF组,ALB指标高于REF组,存在统计学差异(P<0.05,t=2.227/2.754/5.393)。不良反应发生率,RES组为11.11%,REF组为44.44%,前者低于后者,存在统计学意义(P<0.05,/=4.985)。RES组(vs)REF,HBV-DNA转阴率为88.89%(16/10)>55.56%(10/10),存在统计学差异(P<0.05,/=4.985)。结论:失代偿期乙肝肝硬化患者治疗,药物选择恩替卡韦,患者肝功能指标改善明显,不良反应降低,HBV-DNA转阴率上升,临床使用价值较高,可推广。 展开更多
关键词 失代偿期乙肝肝硬化 恩替韦卡 抗病毒治疗 治疗效果
下载PDF
Comparison of the efficacy and adherence of generic and brand-name entecavirs in chronic hepatitis B patients: a multicenter cohort study 被引量:5
6
作者 Ying Xie Hanqiu Zhan +5 位作者 Xiaohong Zhu Yuan Li Ruyi Tian Jing Zhang Shanshan Chen Yanling Zhao 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2021年第12期986-993,共8页
In the present study, we aimed to compare the efficacy and adherence of Runzhong;(generic drug, Chiatai Tianqing,Nanjing) and Baraclude;(branded drug, Bristol-Myers Squibb) in patients with chronic hepatitis B. We col... In the present study, we aimed to compare the efficacy and adherence of Runzhong;(generic drug, Chiatai Tianqing,Nanjing) and Baraclude;(branded drug, Bristol-Myers Squibb) in patients with chronic hepatitis B. We collected patient data from three hospitals within 48 weeks and compared the two groups by using the propensity-score matching method. A total of 4889 patients were enrolled in this study;503 initiated a brand-name drug, and 4386 received a generic drug. There was no significant difference in the rates of CVR(complete virologic response) and VB(virologic breakthrough) between the Runzhong;group and Baraclude;group at 24 and 48 weeks. Similar results for HBeAg loss, medication possession ratio(MPR), and biological response were obtained. Age, gender(HR 0.909(0.842–0.981)), normal baseline ALT rate(HR 0.789(0.731–0.851)), HBeAg-positive rate, and baseline undetectable HBV DNA rate(HR 0.306(0.234–0.399)) were independent factors for achieving CVR. 展开更多
关键词 ENTECAVIR ADHERENCE Generic drug Branded drug
原文传递
Development and validation of an HPLC-UV method for the separation of entecavir optical isomers 被引量:1
7
作者 Dan Huang Daolin Zhang +1 位作者 Nana Wang Xinhui Jiang 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2018年第3期201-208,共8页
A simple and effective high-performance liquid chromatography with ultraviolet detection(HPLC-UV) method was established to determine entecavir optical isomers. With 3 chiral carbon atoms, entecavir had 7 optical is... A simple and effective high-performance liquid chromatography with ultraviolet detection(HPLC-UV) method was established to determine entecavir optical isomers. With 3 chiral carbon atoms, entecavir had 7 optical isomers, including 6 diastereoisomers and 1 enantiomer. The separations were performed on a Symmetrix ODS-AQ C_(18) column(4.6 mm×250 mm, 5 μm) and a Daicel CHIRALPAK AD column(4.6 mm×250 mm, 10 μm), respectively. The detection wavelength was set at 254 nm. The limit of detection(LOD) and the limit of quantification(LOQ) of diastereoisomers(diastereoisomer-1, diastereoisomer-2, diastereoisomer-3) were 0.0371, 0.0376, 0.0377, and 0.124, 0.125, 0.126 μg/mL, respectively. The LOD and LOQ of enantiomer were 0.14 and 0.46 μg/mL, respectively. The precision was within 0.36%, 0.44%, 1.04%, and 0.67% for diastereoisomer-1, diastereoisomer-2, diastereoisomer-3, and enantiomer, respectively. The recoveries of enantiomers ranged from 98.4% to 100.5%. The method could be applied to control the quality of entecavir. 展开更多
关键词 ENTECAVIR Chiral separation DIASTEREOISOMERS ENANTIOMER HPLC-UV
原文传递
Clinical study of warm needling moxibustion combined with entecavir in the treatment of compensated cirrhosis due to chronic hepatitis B 被引量:1
8
作者 NIE Lu ZHANG Juanli 《Journal of Acupuncture and Tuina Science》 CSCD 2022年第3期199-205,共7页
Objective:To investigate the efficacy and possible mechanism of action of warm needling moxibustion combined with entecavir in the treatment of compensated cirrhosis due to chronic hepatitis B(CHB).Methods:Ninety pati... Objective:To investigate the efficacy and possible mechanism of action of warm needling moxibustion combined with entecavir in the treatment of compensated cirrhosis due to chronic hepatitis B(CHB).Methods:Ninety patients were randomly divided into a control group and an observation group,with 45 patients in each group.The control group was given oral entecavir,and the observation group was given additional warm needling moxibustion.The serum alanine transaminase(ALT),aspartate transaminase(AST),albumin(ALB)levels,portal vein internal diameter,splenic vein internal diameter,spleen thickness,and liver hardness were compared before and after treatment.The serum hyaluronic acid(HA),laminin(LN),procollagen typeⅢ(PCⅢ),typeⅣcollagen(Ⅳ-C),interleukin(IL)-21,and platelet-derived growth factor(PDGF)levels were also measured.Results:After treatment,the serum ALT and AST levels decreased(P<0.05),and the serum ALB levels increased(P<0.05)in both groups.The serum ALT and AST levels were lower in the observation group than in the control group(P<0.05),and the ALB level was higher in the observation group(P<0.05).The portal vein internal diameter,splenic vein internal diameter,spleen thickness,and liver hardness values were reduced in both groups after treatment(P<0.05),and were lower in the observation group than in the control group(P<0.05).The serum HA,LN,PCⅢ,andⅣ-C levels were reduced in both groups(P<0.05),and were lower in the observation group than in the control group(P<0.05).In the control group,the serum IL-21 level decreased(P<0.05),but the serum PDGF level did not change significantly(P>0.05);in the observation group,the serum IL-21 and PDGF levels decreased significantly(P<0.05)and were lower than those in the control group(P<0.05).Conclusion:Warm needling moxibustion combined with entecavir treatment can improve liver function,reduce the inner diameters of the portal vein and splenic vein,spleen thickness,and liver hardness,and improve liver fibrosis indicators in patients with CHB cirrhosis,which may be related to the reduction of serum IL-21 and PDGF levels. 展开更多
关键词 Acupuncture-moxibustion Therapy Warm Needling Therapy Acupuncture Medication Combined ENTECAVIR Hepatitis B Chronic Liver Cirrhosis Liver Function Tests
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部